Assignee
IO THERAPEUTICS INC
US·72 granted patents·24 pending applications·394 citations·filing 2012–2025
Top patents by PatentIndex Score
96 records- 0199US10980759B2Treatment of nervous system disorders using combinations of RXR agonists and thyroid hormonesIO THERAPEUTICS INC·Filed 2020·Granted Apr 20, 2021·7 cites·30 claims
- 0299US9907768B2Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapyIO THERAPEUTICS INC·Filed 2017·Granted Mar 6, 2018·25 cites·24 claims
- 0398US10485775B2Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapyIO THERAPEUTICS INC·Filed 2019·Granted Nov 26, 2019·11 cites·20 claims
- 0498US10471030B2Immunomodulatory and differentiating function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapyIO THERAPEUTICS INC·Filed 2019·Granted Nov 12, 2019·14 cites·20 claims
- 0598US10231944B2Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapyIO THERAPEUTICS INC·Filed 2018·Granted Mar 19, 2019·14 cites·20 claims
- 0698US10213401B2Immunomodulatory and differentiating function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapyIO THERAPEUTICS INC·Filed 2018·Granted Feb 26, 2019·18 cites·17 claims
- 0798US10188618B2Treatment of cancer with specific RXR agonistsIO THERAPEUTICS INC·Filed 2017·Granted Jan 29, 2019·29 cites·13 claims
- 0898US10039731B2Treatment of cancer with specific RXR agonistsIO THERAPEUTICS INC·Filed 2017·Granted Aug 7, 2018·29 cites·12 claims
- 0998US10004708B2Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapyIO THERAPEUTICS INC·Filed 2018·Granted Jun 26, 2018·18 cites·20 claims
- 1098US10004709B2Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapyIO THERAPEUTICS INC·Filed 2018·Granted Jun 26, 2018·18 cites·20 claims
- 1198US9717702B2Treatment of cancer with specific RXR agonistsIO THERAPEUTICS INC·Filed 2016·Granted Aug 1, 2017·29 cites·10 claims
- 1298US9655872B2Treatment of cancer with specific RXR agonistsIO THERAPEUTICS INC·Filed 2016·Granted May 23, 2017·29 cites·10 claims
- 1397US11065219B2Treatment of nervous system disorders using combinations of RXR agonists and thyroid hormonesIO THERAPEUTICS INC·Filed 2019·Granted Jul 20, 2021·7 cites·30 claims
- 1497US10973791B2Treatment of nervous system disorders using combinations of RXR agonists and thyroid hormonesIO THERAPEUTICS INC·Filed 2019·Granted Apr 13, 2021·7 cites·30 claims
- 1597US10874627B2Immunomodulatory and differentiating function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapyIO THERAPEUTICS INC·Filed 2019·Granted Dec 29, 2020·6 cites·20 claims
- 1697US10857117B2Treatment of nervous system disorders using combinations of RXR agonists and thyroid hormonesIO THERAPEUTICS INC·Filed 2019·Granted Dec 8, 2020·7 cites·30 claims
- 1797US10835507B2Treatment of muscular disorders with combinations of RXR agonists and thyroid hormonesIO THERAPEUTICS INC·Filed 2016·Granted Nov 17, 2020·12 cites·15 claims
- 1897US10806713B2Treatment of nervous system disorders using combinations of RXR agonists and thyroid hormonesIO THERAPEUTICS INC·Filed 2019·Granted Oct 20, 2020·7 cites·28 claims
- 1997US10532074B2RAR selective agonists in combination with immune modulators for cancer immunotherapyIO THERAPEUTICS INC·Filed 2019·Granted Jan 14, 2020·9 cites·8 claims
- 2097US10517843B2Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapyIO THERAPEUTICS INC·Filed 2019·Granted Dec 31, 2019·7 cites·17 claims
- 2197US10123982B2Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapyIO THERAPEUTICS INC·Filed 2018·Granted Nov 13, 2018·10 cites·11 claims
- 2296US10874628B2Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapyIO THERAPEUTICS INC·Filed 2019·Granted Dec 29, 2020·4 cites·17 claims
- 2396US10596133B2Treatment of cancer with specific RXR agonistsIO THERAPEUTICS INC·Filed 2018·Granted Mar 24, 2020·11 cites·13 claims
- 2496US10590059B2Compounds and synthetic methods for the preparation of retinoid X receptor-specific retinoidsIO THERAPEUTICS INC·Filed 2018·Granted Mar 17, 2020·17 cites·17 claims
- 2595US11793835B2Methods of using RARγ agonists for cancer treatmentIO THERAPEUTICS INC·Filed 2022·Granted Oct 24, 2023·1 cites·17 claims
- 2695US10966950B2Use of an RXR agonist in treating HER2+ cancersIO THERAPEUTICS INC·Filed 2020·Granted Apr 6, 2021·11 cites·17 claims
- 2795US10881628B2Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapyIO THERAPEUTICS INC·Filed 2019·Granted Jan 5, 2021·3 cites·17 claims
- 2894US10363272B2RAR selective agonists in combination with immune modulators for cancer immunotherapyIO THERAPEUTICS INC·Filed 2018·Granted Jul 30, 2019·10 cites·30 claims
- 2993US11919848B2RXR agonist salt form, polymorphs thereof, and uses thereofIO THERAPEUTICS INC·Filed 2023·Granted Mar 5, 2024·1 cites·20 claims
- 3093US10532073B2RAR selective agonists in combination with immune modulators for cancer immunotherapyIO THERAPEUTICS INC·Filed 2019·Granted Jan 14, 2020·3 cites·11 claims
- 3191US10874694B2RAR selective agonists in combination with immune modulators for cancer immunotherapyIO THERAPEUTICS INC·Filed 2019·Granted Dec 29, 2020·2 cites·20 claims
- 3291US10092535B2Treatment of nervous system disorders using combinations of RXR agonists and thyroid hormonesIO THERAPEUTICS INC·Filed 2016·Granted Oct 9, 2018·4 cites·22 claims
- 3389US11786555B2RAR selective agonists in combination with immune modulators for cancer immunotherapyIO THERAPEUTICS INC·Filed 2020·Granted Oct 17, 2023·1 cites·17 claims
- 3489US11779558B2Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapyIO THERAPEUTICS INC·Filed 2020·Granted Oct 10, 2023·1 cites·14 claims
- 3589US11737996B2Immunomodulatory and differentiating function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapyIO THERAPEUTICS INC·Filed 2020·Granted Aug 29, 2023·1 cites·20 claims
- 3689US11166927B2Autoimmune disorder treatment using RXR agonistsIO THERAPEUTICS INC·Filed 2020·Granted Nov 9, 2021·1 cites·21 claims
- 3789US10987330B2Treatment of nervous system disorders using combinations of RXR agonists and thyroid hormonesIO THERAPEUTICS INC·Filed 2020·Granted Apr 27, 2021·1 cites·28 claims
- 3889US9877941B2Treatment of nervous system disorders using combinations of RXR agonists and thyroid hormonesIO THERAPEUTICS INC·Filed 2016·Granted Jan 30, 2018·3 cites·19 claims
- 3987US11976021B2Synthesis of tetrahydronaphthalenols and uses thereofIO THERAPEUTICS INC·Filed 2023·Granted May 7, 2024·0 cites·17 claims
- 4086US10201512B2Autoimmune disorder treatment using RXR agonistsIO THERAPEUTICS INC·Filed 2017·Granted Feb 12, 2019·2 cites·10 claims
- 4186US2025248962A1Treatment of nervous system disorders using combinations of rxr agonists and thyroid hormonesIO THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 4285US12325685B2RXR agonist salt form, polymorphs thereof, and uses thereofIO THERAPEUTICS INC·Filed 2024·Granted Jun 10, 2025·0 cites·9 claims
- 4384US12115193B2Methods of using RARγ agonists for cancer treatmentIO THERAPEUTICS INC·Filed 2023·Granted Oct 15, 2024·0 cites·6 claims
- 4484US10919835B2Compounds and synthetic methods for the preparation of retinoid X receptor-specific retinoidsIO THERAPEUTICS INC·Filed 2020·Granted Feb 16, 2021·1 cites·17 claims
- 4584US10485778B2Treatment of nervous system disorders using combinations of RXR agonists and thyroid hormonesIO THERAPEUTICS INC·Filed 2018·Granted Nov 26, 2019·1 cites·28 claims
- 4683US11793781B2Autoimmune disorder treatment using RXR agonistsIO THERAPEUTICS INC·Filed 2022·Granted Oct 24, 2023·0 cites·23 claims
- 4783US11648223B2Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapyIO THERAPEUTICS INC·Filed 2022·Granted May 16, 2023·0 cites·17 claims
- 4883US11576881B2Autoimmune disorder treatment using RXR agonistsIO THERAPEUTICS INC·Filed 2021·Granted Feb 14, 2023·0 cites·21 claims
- 4983US2025026714A1METHODS OF USING RARy AGONISTS FOR CANCER TREATMENTIO THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 5082US10842764B2Treatment of nervous system disorders using combinations of RXR agonists and thyroid hormonesIO THERAPEUTICS INC·Filed 2019·Granted Nov 24, 2020·0 cites·30 claims
Showing the top 50 of 96 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when IO THERAPEUTICS INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →